79th European Atherosclerosis Society Congress (EAS 2011)
Webcasted Presentations

Search’n Build™

Introduction
by Olov Wiklund
2011-06-26 3 minutes  
CHALLENGES TO EFFECTIVE CARDIOVASCULAR RISK MANAGEMENT
by Alberto Zambon
2011-06-26 16 minutes  
HOT TOPICS RELATING TO THE CHALLENGES FACED IN EFFECTIVE CARDIOVASCULAR RISK ...
by Panel Discussion
2011-06-26 8 minutes  
IMPLEMENTING EFFECTIVE CVD RISK MANAGEMENT IN CLINICAL PRACTICE
by David A. Wood
2011-06-26 13 minutes  
HOT TOPICS IN THE IMPLEMENTATION OF GUIDELINES IN CLINICAL PRACTICE
by Panel Discussion
2011-06-26 9 minutes  
NEW OPPORTUNITIES FOR CARDIOVASCULAR DISEASE PREVENTION
by Stephen Nicholls
2011-06-26 20 minutes  
HOT TOPICS IN TARGETED INTERVENTION OF CVD RISK
by Panel Discussion
2011-06-26 10 minutes  
CLOSE
by Andrew A. Tonkin
2011-06-26 6 minutes  
CHAIRMAN'S INTRODUCTION
by Wolfgang W. Koenig
2011-06-26 1 minute  
HDL FUNCTION AND REVERSE CHOLESTEROL TRANSPORT IN HUMANS: CAN THEY BE PROMOTE...
by Marina M. Cuchel
2011-06-26 20 minutes  
THE ROLE OF REDUCED CETP ACTIVITY AS A POTENTIAL THERAPEUTIC TARGET TO DECREA...
by Bryan B. Brewer
to be announced! (Waiting for speaker approval)
VASCULAR FUNCTION - THERAPEUTIC TARGET OR CARDIOVASCULAR RISK MARKER
by John Deanfield
2011-06-26 19 minutes  
Discussion
by Panel Discussion
2011-06-26 14 minutes  
SUMMARY AND CLOSE
by Chris Packard
2011-06-26 2 minutes  
INTRODUCTION OF THE ANITSCHKOW PRIZE WINNER
by John Chapman
2011-06-26 6 minutes  
THE ANITSCHKOW LECTURE: CETP INHIBITION AS A STRATEGY TO REDUCE CARDIOVASCULA...
by Philip Barter
2011-06-26 34 minutes  
NEW INSIGHTS INTO THE ETIOLOGY AND PATHOPHYSIOLOGY OF HEREDITARY DYSLIPIDEMIAS
by Helen Hobbs
2011-06-27 25 minutes  
POST-PRANDIAL LIPID METABOLISM
by Stephen Young
2011-06-27 22 minutes  
THE GUT MICROBIOTA AS AN ENVIRONMENTAL FACTOR THAT REGULATES HOST PHYSIOLOGY ...
by Fredrik Bäckhed
to be announced! (Waiting for speaker approval)
DIVERSITY OF HDL PARTICLES - A CHALLENGE FOR TREATMENT
by John Chapman
2011-06-27 35 minutes  
PATHOLOGY OF THE VULNERABLE PLAQUE: WHAT DOES IT LOOK LIKE?
by Erling Falk
2011-06-28 24 minutes  
THE CELLULAR BIOLOGY OF PLAQUE NECROSIS
by Ira Tabas
2011-06-28 31 minutes  
NEW IMAGING POSSIBILITIES IN ATHEROSCLEROSIS
by James Rudd
2011-06-28 29 minutes  
PHARMACOLOGICAL TREATMENT OF THE VULNERABLE PLAQUE
by Peter Libby
to be announced!
CETP INHIBITION: THE NEXT FRONTIER IN CARDIOVASCULAR THERAPY
by Bryan B. Brewer
2011-06-28 44 minutes  
 
CO-CHAIR'S INTRODUCTION and HDL-C: ROLE AS A RISK MODIFIER
by Philip Barter
2011-06-28 22 minutes  
PITAVASTATIN - AN OVERVIEW
by Yasushi Saito
2011-06-28 10 minutes  
PITAVASTATIN: NOVEL EFFECTS ON LIPID PARAMETERS
by John Chapman
2011-06-28 25 minutes  
PITAVASTATIN: CLINICAL EFFECTS FROM THE LIVES STUDY
by Tamio Teramoto
2011-06-28 14 minutes  
Panel Discussion
by Panel Discussion
2011-06-28 7 minutes  
Closing remarks
by Philip Barter
2011-06-28 2 minutes  
THE ROLE OF INFLAMMATORY BIOMARKERS IN DAILY DECISION MAKING
by Borge Nordestgaard
2011-06-29 25 minutes  
IMMUNE MODULATION/VACCINATION TO TREAT AND PREVENT ATHEROSCLEROSIS
by Jan Nilsson
2011-06-29 30 minutes  
WHAT IS A HEALTHY DIET, AS DEFINED BY THE CRITERIA OF EVIDENCE-BASED MEDICINE?
by Gabriele Riccardi
2011-06-29 30 minutes  
THE NEW EAS/ESC GUIDELINES TO TREAT DYSLIPIDEMIAS
by Alberico L. Catapano
2011-06-29 25 minutes